Hepion Pharmaceuticals (NASDAQ: HEPA) Reports Promising Phase 2 Trial Results for NASH TreatmentRenocofilstat's Positive Outcomes Reinforce Antifibrotic Action Hepion Pharmaceuticals, a clinical stage biopharmaceutical company focusing on AI-assisted therapeutic drug development, recently
